Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

August 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Here’s how COVID-19 vaccine BNT162b1 produces human antibody and helper T-cell responses

Hong Kong PhD Fellowship Scheme (HKPFS) 2021-2022

Pet bearded dragons droppings cause Salmonella outbreak: Question is are they safe?

Here’s how COVID-19 vaccine BNT162b1 produces human antibody and helper T-cell responses
  • BiotechToday
  • India
  • World

Here’s how COVID-19 vaccine BNT162b1 produces human antibody and helper T-cell responses

bioxone October 4, 2020October 4, 2020

Ayooshi Mitra, Amity University Kolkata

To avert the spread of the pandemic of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), a successful vaccine is needed. In an examination directed recently, safety, tolerability, and neutralizer reaction information from an on-going placebo-controlled treatment observer-blinded phase 1/2 coronavirus disease 2019 (COVID-19) vaccine trial BNT162b1, a lipid nanoparticle (LNP) nucleoside-modified messenger RNA (mRNA) encoding the SARS-CoV-2 spike protein1 receptor-binding domain (RBD) was accounted for. Here, antibody and T-cell responses following BNT162b1 vaccination in a second, non-randomized, Phase 1/2 open-label trial in healthy adults aged 18-55 years were presented. 

Two dosages of 1 to 50 μg of BNT162b1 brought strong CD4 + and CD8 + T-cell and antibody responses, with RBD-binding IgG concentrations clearly above those in the COVID-19 sample (HCS) panel. For the 43rd day of SARS-CoV-2 serum neutralizing, mean values were 0.7-fold (1 μg) to 3.5-fold (50 μg) of the HCS panel. Immune sera broadly neutralized pseudoviruses with various SARS-CoV-2 spike variants. Most participants had positive T cell immune responses with CD8 + RBD-specific and CD4 + T-cell development. The tough RBD-specific antibody, T-cell, and favourable cytokine reactions induced by the BNT162b1 mRNA vaccine suggest multiple advantageous mechanisms with the potential to defend against the COVID-19.

References: Sahin, U., Muik, A., Derhovanessian, E. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature (2020). https://doi.org/10.1038/s41586-020-2814-7 https://www.nature.com/articles/s41586-020-2814-7

Also read: Can high systemic inflammation biomarkers during puberty result in breast cancer?

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Antibody CORONAVIRUS COVID-19 cytokine reactions mRNA mRNA vaccine pandemic receptor binding SARS-CoV-2 successful vaccine T-cell and B-cell T-cell response VACCINE

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • India
  • World

Pet bearded dragons droppings cause Salmonella outbreak: Question is are they safe?

bioxone October 4, 2020

Prama Ghosh, Amity University Kolkata 13 people from 8 states have been infected with the outbreak strain of Salmonella muenster linked to bearded dragons, as of 25th September, according to the latest information released from the Centers for Disease Control and Prevention (CDC).  Pet bearded dragons are likely the source of this outbreak as shown […]

Salmonella

Related Post

  • BiotechToday
  • World

Are COVID-19 patients diagnosed with Down Syndrome prone to severe diseases?

bioxone October 18, 2020October 18, 2020

Sayak Banerjee, Amity University Kolkata Down syndrome (DS), also known as trisomy 21 is the most persistent aneuploidy characterized by a genetic disorder caused due to the triplication of the 21st human chromosome. This syndrome is particularly associated with the development of congenital heart disease, sleep apnoea, obesity, diabetes, premature ageing, and higher sensitivity to […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Ebola-like Marburg virus – first case detected in West Africa

BioTech Today August 13, 2021August 12, 2021

Shrestha Dutta, Amity University Kolkata Ebola-like Marburg virus disease (MVD), earlier known as Marburg hemorrhagic fever, is a lethal disease in people. The infection causes extreme viral hemorrhagic fever in the patient. Marburg and Ebola infections are both members of the Filoviridae family (filovirus). Both the diseases are the same clinically but are caused by […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Drug development from traditional to recent methods

bioxone June 7, 2021June 7, 2021

Varuni Ankolekar, Clinical Data Manager Traditionally, the discovery of drugs was done by recognizing the active ingredients from traditional remedies or unexpectedly.  Later, Scientists discovered that the interaction of specific chemicals in the drug with biological molecules of the human body serves the purpose of the drug. Later, Chemical pharmacological approaches were made to identify […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy